Roche and Eli Lilly's Blood-Based Alzheimer's Test Wins First FDA Clearance for Primary Care

If you've ever sat with someone you love while a doctor tries to explain memory loss, you know how long and uncertain that road usually is. This week, part of that road got shorter.

Roche's Elecsys pTau181 test, developed with Eli Lilly, just became the first blood-based Alzheimer's biomarker test cleared by the FDA for use in primary care, not just specialist neurology clinics. It works from a simple blood draw, measuring a form of tau protein tied to Alzheimer's-related amyloid pathology. It's meant for patients 55 and older who are showing early signs of cognitive decline.

In a trial of 312 people, the test correctly ruled out Alzheimer's 97.9% of the time.

Until now, getting a real answer meant a costly PET scan or a spinal tap, usually only available through a specialist, usually after a long wait. A test your regular doctor can order changes that math. It won't replace deeper workups when something looks concerning, but it means fewer families spend months wondering, and it frees up specialists for the patients who need them most.

That's not a small thing. That's someone's mother, father, or partner getting an answer sooner.

Sources: Roche — Roche's Elecsys pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology · BioSpace — Roche, Lilly Win First FDA Nod for Alzheimer's Blood Test for Primary Care Use